Claims Review to Be Enhanced for Oncology Drugs and Services for Government Programs, Effective June 1, 2025
AI Summary
Effective June 1, 2025, enhanced claims review will be implemented for oncology drugs and associated services for Medicare Advantage and Medicaid members. Claims lacking appropriate procedure and diagnosis codes will face delays or denials, requiring strict adherence to standard coding guidelines including ICD-10, HCPCS, and CPT codes.
Action Required
By June 1, 2025: Billing team must ensure all oncology drug claims for Medicare Advantage and Medicaid members include accurate procedure and diagnosis code combinations per ICD-10, HCPCS, and CPT guidelines. Review current oncology billing workflows and update staff training on proper coding requirements. Inaccurately coded claims will result in denied or delayed payment.
Plan Types
Medicare Advantage, Medicaid
States
TX
Specialties
oncology